Chemify

Research on the record

• 2026-04-07Lee Cronin, Chemify's founder, argues in PNAS that a Chemputer with step-by-step error correction could in principle make any stable molecule, and re-reads 117 robot runs to back itLevel 3 · Checked against existing evidence
• 2026-04-03An LLM agent from Cronin's group, whose founder leads Chemify, turns published procedures into robot code and runs six of themLevel 4 · Tested in the physical world
• 2026-03-27Cronin's group, whose founder leads Chemify, makes kinase inhibitors on a Chemputer and finds one that beats regorafenib in colorectal organoidsLevel 4 · Tested in the physical world

Graded by how far the evidence went, not how good the result is. See the methodology.

People

Only people the AI4S.fyi record has named: in a round, a timeline entry, commentary, an interview or a sourced role. Not the full team.

Funding rounds tracked

• 2026-09-16Series B extension · Series B extended to £51.9M ($70M) in totalconfirmedStated use: second-generation Chemifarm, new Glasgow HQ
• 2026-02-12Strategic · undisclosedreportedLed by Zeon VenturesStated use: alongside a deal to make compounds and materials for Zeon
• 2025-10-21Series B · more than $50MconfirmedLed by Wing Venture Capital, Insight Partners · With 8VC, Triatomic Capital, Blueyard, Rockspring, EosStated use: scale Chemputation and the Chemifarm facilities
• 2023-08-03Series A · $43MconfirmedLed by Triatomic Capital · With Horizon Ventures, Possible Ventures, Alix Ventures, Eos, BlueYard Capital, UK Government Innovation Accelerators, Rocketship VenturesStated use: grow the company and its platform

Each round links to its line on the funding record, with its source.

Also in Autonomous labs on the funding board

The other companies the funding board files under the same field, latest round first. A list of what the record tracks, not a ranking or a market map.

• 2026-10-22Warp SciencesRound (unnamed) · $215MA US chemistry contract research organisation that makes the molecules drug-discovery teams order, starting with variations of a lead compound for lead optimisation. Chemists guide the work while the company automates more of it with AI and robotics and trains models on the data its experiments produce. It says it has no drug pipeline of its own.
• 2026-10-06Multiply LabsSeries B · $75MBuilds robotic clusters that run the manual steps of making cell and gene therapies and other biologics, working with the drugmaker's existing equipment; the drugmakers own and operate the robots.
• 2026-09-21Woshi TechnologyRound (unnamed) · over 100M yuan across several rounds in the past yearA structured chemistry database, AI models for synthesis planning and robotic labs from milligram to kilogram scale, used by chemicals, battery and pharma companies.
• 2026-09-16Deep MaterialA+ · nearly 100M yuanDesigns metal alloys with its own models and an automated high-throughput lab, then supplies the materials to 3C, aerospace and fusion customers.
• 2026-09-02RhinovatePre-A · several hundred million yuanPairs an AI-scientist agent with robotic labs and pilot scale-up to develop polymers, carbon-fibre composites and battery electrolytes, incubated at Peking University's Shenzhen campus.
• 2026-08-26TransfyrSeed · $25MPuts sensors and multimodal models into labs to record how scientists actually carry out an experiment (their actions, the environment, instrument readings) and turns that record into data for troubleshooting, tech transfer, training and robot instructions. It runs an in-house wet lab that generates its own training data.

All 14 in this field →